Mediwound (MDWD) & Ocera Therapeutics (OCRX) Critical Analysis

Mediwound (NASDAQ: MDWD) and Ocera Therapeutics (NASDAQ:OCRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Risk & Volatility

Mediwound has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Comparatively, Ocera Therapeutics has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.

Earnings and Valuation

This table compares Mediwound and Ocera Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mediwound $1.56 million 81.50 -$18.88 million ($0.98) -4.80
Ocera Therapeutics $610,000.00 77.79 -$26.89 million ($0.97) -1.85

Mediwound has higher revenue and earnings than Ocera Therapeutics. Mediwound is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Mediwound and Ocera Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mediwound 0 0 5 0 3.00
Ocera Therapeutics 0 3 1 0 2.25

Mediwound currently has a consensus price target of $9.80, suggesting a potential upside of 108.51%. Ocera Therapeutics has a consensus price target of $1.92, suggesting a potential upside of 7.08%. Given Mediwound’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Mediwound is more favorable than Ocera Therapeutics.


This table compares Mediwound and Ocera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mediwound -904.26% -246.58% -39.43%
Ocera Therapeutics N/A -228.93% -103.71%

Institutional and Insider Ownership

29.5% of Mediwound shares are held by institutional investors. Comparatively, 17.7% of Ocera Therapeutics shares are held by institutional investors. 7.2% of Ocera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


Mediwound beats Ocera Therapeutics on 8 of the 13 factors compared between the two stocks.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with's FREE daily email newsletter.

Leave a Reply